^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Breast Cancer
    Drug:letrozole (Aromatase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    04/05/2018
    Excerpt:
    Femara is an aromatase inhibitor indicated for:...Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy....First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer.